Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodentine vs TheraCal LC for Indirect Pulp Capping
NCT03741816Unknown
- Sponsor
- UVEG
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of TheraCal LC in dental caries and reversible pulpitis (2 arms), sponsored by UVEG. Primary endpoint: Response to pulp sensibility testing at 12 months. Status: unknown.
02
Drugs
TheraCal LC
03
Conditions
dental cariesreversible pulpitis
Beyond the preview
Go deeper on NCT03741816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03741816.